Other Information.
−Removed: the period ended June 30, 2025, none of our directors or executive officers adopted or terminated any “Rule 10b5-1 trading arrangement”
−Removed: or “non-Rule 10b5-1 trading arrangement” (as each item is defined Item 408(a) of Regulation S-K).
−Removed: Certificate of Incorporation of Kairos Pharma, Ltd.
−Removed: filed with the Secretary of State of the State of Delaware, dated May 10, 2023 (incorporated by reference to Exhibit 3.5 to the Company’s Registration Statement on Form S-1, filed on August 16, 2024).
−Removed: Bylaws of Kairos Pharma, Ltd.
−Removed: (Delaware) (incorporated by reference to Exhibit 3.6 to the Company’s Registration Statement on Form S-1, filed on August 16, 2024).
−Removed: Form of Representative’s Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-1, filed on August 16, 2024)
+Added: the period ended September 30, 2025, none of our directors or executive officers adopted or terminated any “Rule 10b5-1 trading
+Added: arrangement” or “non-Rule 10b5-1 trading arrangement” (as each item is defined Item 408(a) of Regulation S-K).
+Added: of Incorporation of Kairos Pharma, Ltd.
+Added: filed with the Secretary of State of the State of Delaware, dated May 10, 2023 (incorporated
+Added: by reference to Exhibit 3.5 to the Company’s Registration Statement on Form S-1, filed on August 16, 2024).
+Added: of Kairos Pharma, Ltd.
+Added: (Delaware) (incorporated by reference to Exhibit 3.6 to the Company’s Registration Statement on Form
+Added: S-1, filed on August 16, 2024).
+Added: of Representative’s Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form
+Added: S-1, filed on August 16, 2024)
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
4 unchanged sentences
Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: Services Agreement, dated June 10, 2025, between Kairos Pharma Ltd.
−Removed: and Baretto Pacific Corporation (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K dated June 12, 2025).
+Added: Novation Agreement, entered into October 1, 2025 but effective April 17, 2025, between Kairos Pharma, Ltd., Enviro Therapeutics, Inc.
+Added: and Cedars-Sinai Medical Center (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K dated October 1, 2025).
+Added: Novation Agreement, dated October 7, 2025, between Kairos Pharma, Ltd., Enviro Therapeutics, Inc.
+Added: and Tracon Pharmaceuticals, Inc.
+Added: (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K dated October 1, 2025).
+Added: Form of Amendment No.
+Added: 83 to Sales Agreement, dated November 12, 2025, between Kairos Pharma Ltd.
+Added: and Lonza Sales AG.
XBRL Instance Document-the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the
10 unchanged sentences
the undersigned, thereunto duly authorized.
−Removed: August 12, 2025
+Added: November 14, 2025
Executive Officer and Chairman of the Board of Directors
−Removed: (principal executive officer)
+Added: executive officer)
Douglas Samuelson
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.